Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | EBP | Q15125 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21165831 | 1.00 | KDM4E (0.36) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL104800 | 0.79 | PDK1 (0.38) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL10130710 | 0.79 | PDK1 (0.38) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL10130709 | 0.79 | PDK1 (0.38) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL1911485 | 0.79 | PDK1 (0.38) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL19730584 | 0.76 | — | — | |
| SCHEMBL24044808 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL24654733 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL20192243 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1GAACYP2C9HPGD | |
| SCHEMBL19701920 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1GAACYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | KDM4E 4219/4885ALDH1A1 3871/4885GAA 1228/4885 |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KDM4E 1291/4885ALDH1A1 1067/4885GAA 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.